The data used to create the tables and figures in this paper can be accessed without restrictions at <https://doi.org/10.5281/zenodo.3258330>.

Introduction {#sec005}
============

All health systems have budget constraints and limited resources. Methods for health economic evaluations, like cost-effectiveness analysis (CEA), are essential in health policy and are extensively used to rank health services by their expected efficiency \[[@pone.0235955.ref001]\]. However, few people endorse strict health maximisation \[[@pone.0235955.ref002]\], and fairness criteria may be included in such rankings \[[@pone.0235955.ref003], [@pone.0235955.ref004]\]. For example, one may give higher priority to interventions that target those with the most severe illnesses \[[@pone.0235955.ref005]--[@pone.0235955.ref007]\], especially in relation to decisions about the pricing and reimbursement of new medicines and devices \[[@pone.0235955.ref008], [@pone.0235955.ref009]\]. Policy makers in countries like Norway \[[@pone.0235955.ref010]\] and the Netherlands \[[@pone.0235955.ref011]\] have already started using severity measurement methods.

In this paper, the terms "illness", "disease" and "condition" are used interchangeably, and include all adverse medical conditions, such as injuries, syndromes, birth defects, and infections. The term "severity of illness" involves both substantial value disagreements and a wide range of interpretations \[[@pone.0235955.ref012], [@pone.0235955.ref013]\]. To sidestep misunderstandings, we use the concept of "health status at disease onset" rather than severity of illness. Three perspectives on how to measure health status dominate in the literature. One view considers current health \[[@pone.0235955.ref014]\], one considers health over future years \[[@pone.0235955.ref015]\], and one considers health over the lifetime \[[@pone.0235955.ref016]--[@pone.0235955.ref018]\]. In this paper we conform to the last and focus on the lifetime health that individuals with a particular illness are expected to achieve before they die \[[@pone.0235955.ref018]\]. Technically, only the future health (after disease onset) is affected directly by the disease, but lifetime health is the sum of past (before disease onset) and future health expectancies. These differences in years of healthy life lived before disease onset among people with different diseases also inform the potential lifetime health that can be attained and are part of measuring health status by the view we use.

Clinical definitions of severity of illness often include urgency, but our definition of health status does not. Urgency pertains to the timing of treatment and how this influences the prognosis of a condition. Conditions that are severe from a lifetime health perspective, like multiple sclerosis in young patients, do not necessarily require urgent interventions. To underscore that we use a lifetime health perspective when measuring health status, we will from now on use the term "lifetime health" instead of "health status".

The Global Burden of Disease (GBD) study provides critical summary measures of population health that are relevant when evaluating and comparing health systems \[[@pone.0235955.ref003]\]. These measures include disability-adjusted life years (DALY) and health adjusted life expectancy (HALE). GBD uses a prevalence-based approach, where DALYs are calculated for a set of diseases by summing the years of life lost (YLL) compared to a reference life expectancy and years lived with disability (YLD) in one particular year due to each disease \[[@pone.0235955.ref019]\]. For a particular condition and a particular year, YLL is the sum of all the years lost for the individuals who died from the condition during that year. The reference is the age-adjusted life expectancy (LE) from a life table derived from the mortality rates in the locations with the lowest age-specific mortality in the GBD study \[[@pone.0235955.ref020]\]. YLD, on the other hand, is the sum of the health loss due to the condition during the year across people living with the condition \[[@pone.0235955.ref021]\]. DALYs aggregated from YLLs and YLDs are a measure of overall population burden. HALE measures the life expectancy in a population, adjusting for the disability experienced in the population, using age-specific mortality rates and YLDs *per capita* \[[@pone.0235955.ref022]\]. A major limitation of these measures is that they do not capture how the condition affects the distribution of lifetime health at disease onset across individuals in the population.

We propose a framework where this distribution is an integral part. A key component in this framework is the new metric Health Adjusted Age at Death (HAAD). In this paper, we present a method for estimating HAAD, and show how to use the estimated HAAD to rank conditions at disease onset. We consider four conditions and six countries to illustrate how and why our framework is relevant for priority setting in health care and the measurement of population health.

Methods {#sec006}
=======

Definition of HAAD {#sec007}
------------------

HAAD measures lifetime health for individuals with specific conditions and consists of two components: past health and future expected health. We obviously do not know the actual time of death for people dying in the future, but we do have some knowledge about the expected distribution across individuals. Consider, for example, two people aged 30 (Ann) and 50 (Bob) who each get a disease. The prognosis for Ann is that she will certainly die within 21 years, but we do not know exactly when. The risk of dying is 99% before her 50^th^ birthday, but there is also a 1% chance that she will die in her 51^st^ year. Bob, however, will certainly die before he is 51. For simplicity in this example, although we will use the term "lifetime health", we disregard health/disability adjustment for time with illness and focus only on their age at death. Because there is a 99% probability that Ann will die at a younger age than Bob will, Ann's lifetime health is lower than Bob's in terms of total length of life (past life plus expected future life), even though Bob's expected future life is shorter. This is true even if there is a 1% chance that Ann too will die in her 51^st^ year. Health adjustment complicates matters, as we will discuss below, but the principles are the same. Of course, HAAD needs to go beyond hypothetical two-person cases to become a relevant health metric for priority setting in countries with millions of individuals and multiple diseases. HAAD enables comparison of both average lifetime health (aHAAD) and distribution of lifetime health between individuals with different diseases (e.g., at disease onset, Ann's disease will have a very different HAAD distribution than Bob's disease). Methods for calculating aHAAD and the HAAD distribution within disease conditions are presented in the next sections.

Data {#sec008}
----

For illustrative purposes, we consider four conditions (acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), schizophrenia, and epilepsy) in six countries (Ethiopia, Haiti, China, Mexico, United States and Japan). The diseases have distinct properties that highlight certain characteristics of HAAD. The two leukemias are fatal, but the incidence of ALL peaks at both young and older age groups, whereas AML incidence peaks at old age groups only. Schizophrenia has large impact on disability over many years, and there are variations in both mortality and morbidity of epilepsy across countries. We consider the leukemias in a US setting, and then we compare schizophrenia and epilepsy across the six countries, representing low-, middle- and high-income settings with different age distributions, levels of health systems development, and access to healthcare among their populations. Estimates for all countries and for all diseases in 2017 are obtained from the freely available GBD results tool \[[@pone.0235955.ref023]\]. The GBD Study produces cause-specific estimates of deaths, incidence, and prevalence by country, year, age, and sex, utilizing demographic methods \[[@pone.0235955.ref024], [@pone.0235955.ref025]\], ensemble models \[[@pone.0235955.ref026]\] using vital registration and verbal autopsy data about causes of death, and Bayesian meta-regression \[[@pone.0235955.ref027]\] using data from reviews of literature, registries, and hospitals. [Table 1](#pone.0235955.t001){ref-type="table"} describes variables available in the GBD database, and how they are used to derive other important variables.

10.1371/journal.pone.0235955.t001

###### Description of data and variables used to calculate Health Adjusted Age at Death (HAAD), the GBD 2017 study \[[@pone.0235955.ref020]\] is source for all calculations.

![](pone.0235955.t001){#pone.0235955.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable         Description
  ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PIM              *Period of increased mortality*. From expert opinions. Number of years with increased mortality after disease onset. The rate at which mortality declines in the PIM is specific for each condition. For simplicity, PIM = 100 for chronic diseases. We use PIM = 5 for the leukemias.

  PID              *Period of increased disability*. From expert opinions. Number of years with increased disability after disease onset. The rate at which disability declines in the PID is specific for each condition. For simplicity, PID = 100 for chronic diseases. We use PID = 5 for the leukemias.

  Pop              *Population size*, *per 5-year age interval*. From GBD 2017.Transformed to 1-year age intervals by distributing individuals evenly across the five years.

  P~D~             *Prevalence (per capita) of disease per 5-year age interval*.From GBD 2017.Assumed to be the same in all 1-year intervals.

  I~D~             *Incidence (per capita) of disease per 5-year age interval*. From GBD 2017.Assumed to be the same in all 1-year intervals.

  M~D~             *Disease specific rate of death per 5-year age interval*, *for total population*. From GBD 2017. Assumed to be the same in all 1-year intervals.

  Q                *All cause probability of death in single-year intervals*, *for a total population (i*.*e*., *baseline mortality)*. From GBD 2017. q = 1 − exp(−M~All\ causes~) Converted from single-year M~D~ using common demographic approximation \[[@pone.0235955.ref028]\].

  YLD~D~           *Years Lived with Disability (per capita in one year) of disease in 5-year age intervals*.\
                   From GBD 2017. Assumed to be the same in all 1-year intervals.

  **Derived**      

  em~D~            Excess mortality due to disease (case fatality rate). These are not given directly in GBD, but can be calculated using $em_{D}\left( {age} \right) = \frac{M_{D}\left( {age} \right)}{P_{D}\left( {age} \right)}$. This is the extra risk of dying for individuals with disease that is caused directly by the disease itself. Note that this is different from M~D~, which is the risk of dying from a particular disease for any individual in the population.

  q~D~             Probability of death due to disease and baseline mortality. These are not given directly in GBD, but can be calculated using q~D~(age) = 1 − exp(−(M~All\ causes~(age) − M~D~(age) + em~D~(age))). Substituting em~D~ into q~D~ yields $q_{D}\left( {age} \right) = 1 - {\text{exp}\mspace{720mu}\left( {- \left( {M_{All\mspace{720mu} causes}\left( {age} \right) + M_{D}\left( {age} \right)\left( {\frac{1}{P_{D}\left( {age} \right)} - 1} \right)} \right)} \right)}$. We can see that if P~D~ = 1, meaning that all individuals in the population have a disease, q~D~ simply becomes q. This is also the case if there is no mortality from disease, so that M~D~ = 0.

  $q_{D}^{PIM}$    During the period of increased probability of death due to disease, q~D~ is used for PIM years. After the period, q~D~ returns to q.

  Dw               Background disability weight from the population overall (0 is no disability and 1 is death). dw(age) = YLD~All\ causes~. Note that YLD~All\ causes~(age) is *per capita*.

  dw~D~            Average disability weight due to the disease of interest (0 is no disability and 1 is death). ${dw}_{D}\left( age \right) = \frac{{YLD}_{D}\left( age \right)}{P_{D}\left( age \right)}$. Note that YLD~D~(age) is *per capita*.

  $dw_{D}^{PID}$   In the GBD study, disability weights are aggregated by subtracting from 1 the product of 1 minus the two disability weights. To calculate the disability weight during the period of increased disability during illness, we can combine the "background" disability (i.e., disability from other causes than D) on average and the disability specifically from the disease on average. $dw_{D}^{PID}\left( age \right) = 1 - \left( {1 - {dw}_{Background}\left( age \right)} \right)\left( {1 - {dw}_{D}\left( age \right)} \right)$. To calculate the background disability, we treat YLD rates (i.e., YLD *per capita*) in the population as average disability weights for a given person and solve for the background disability by breaking down the all-cause disability weight into disability from the specific cause and from other causes. YLD~All\ Causes~(age) = 1 − (1 − dw~Background~(age))(1 − YLD~D~ age)) Solving for the background disability and inserting into the first equation, the disability weight during the period of increased disability is ${dw}_{D}^{PID}\left( age \right) = 1 - \left( {1 - \frac{{YLD\mspace{720mu}}_{All\mspace{720mu} causes}\left( age \right) - {YLD}_{D}\left( age \right)\mspace{720mu}}{1 - {YLD}_{D}\left( age \right)}} \right)\left( {1 - {dw}_{D}} \right)$. After the period, dw returns to that of the baseline population (dw). Note that YLD~All\ causes~(age) and YLD~D~(age) are *per capita*.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The GBD database gives the parameters from [Table 1](#pone.0235955.t001){ref-type="table"} in 5-year age groups to age 95. The under-5 age group is split into "less than one year old" (\<1 group) and "1--4 years old". To obtain single-year age estimates, we undertake the following procedures. For *pop*, we divide the population in the 4- and 5-year age groups evenly by single-year ages, and the terminal age group (95 plus) is divided equally in five parts from 95 to 99. For example, if 500 000 individuals are in the 20--24 age group, we will assume that there are 100,000 20-year olds, 100,000 21-year olds, and so on. For P~D~, I~D~, dw, dw~D~, q(age), and M~D~(age), we assume that the rates (or disability weights) are the same for each single-year age in the aggregate age groups. For example, if dw~D~ was 0.2 in the 20--24 age group, we assume that it was 0.2 for 20-year olds, 0.2 for 21-year olds, and so on.

Part I: Estimating disease-specific age at death {#sec009}
------------------------------------------------

To estimate age at death (AD) from the GBD data described in previous sections, we use standard lifetable methodology, so that AD of an individual is simply $$AD\left( {age} \right) = age + {LY}^{future}\left( {age} \right),$$ where "age" is the age of the individual and LY^future^ is the number of life years they have left to live at their respective age. LY^future^ is not known until the individual dies, but its distribution can be estimated as follows. First, we choose Y, the maximum age in our lifetable, by setting the chance of surviving from age Y to Y+1 to zero. In principle, Y can be any age, but we have used Y = 99 throughout this paper. Then we calculate the number of people who are expected to die at different ages in the years to come until they reach age Y. This can be done using an upper diagonal (Y + 1) × (Y + 1) matrix, $$\mathbb{N}_{AD} = \begin{bmatrix}
N_{0,0} & N_{0,1} & N_{0,2} & \cdots & N_{0,Y} \\
 - & N_{1,1} & N_{1,2} & \cdots & N_{1,Y} \\
 - & - & N_{2,2} & \cdots & N_{2,Y} \\
 - & - & - & \ddots & \vdots \\
 - & - & - & \cdots & N_{Y,Y} \\
\end{bmatrix}.$$

In each element of ℕ~AD,~ N~c,d~, the *c* denotes the current age and the *d* denotes the expected age at death. For example, N~3,12~ is the number of today's 3-year-olds who will die at age 12. Each N~c,d~ is calculated using standard lifetable methodology \[[@pone.0235955.ref022]\], based on the assumption that q(age) remains the same in the future. In other words, {N~c,0~, N~c,1~, ..., N~c,Y~} is the distribution of expected age at death for an individual with current age *c*. We see that summing the rows, $\sum\limits_{d = 0}^{Y}N_{c,d}$, yields the population age structure (pop). Further, summing the columns, $\sum\limits_{c = 0}^{Y}N_{c,d}$, gives the number of people that we expect to die at age *d*. That is, the expected number of people for which AD = *d*. The sum ∑~c~∑~d~N~c,d~ is the total current number of people at all ages. In our calculations, we use Y = 99. Note that it follows from the assumption of a static q(age) that average LY^future^ is the same as LE. From ([1](#pone.0235955.e008){ref-type="disp-formula"}) we see that AD is dominated by LY^future^ for young children, and by age for very old people.

Before we break the analysis into diseases, we start by analyzing total figures for one country, as this is familiar for most readers and perhaps more intuitive. [Fig 1](#pone.0235955.g001){ref-type="fig"} shows the estimated distribution of AD for all age groups in the total population of the United States in 2017. In the left panel, individuals alive in 2017 are ranked by their current age, and the right panel ranks them by AD. Now we can see that we expect that around 22.6 million people (7%) in the US have AD \< 60 years. In comparison, the proportion is much higher in Ethiopia (16%) and Haiti (20%). Note that by simply focusing on LE, we would know nothing about such distributional characteristics.

![Estimated distribution of Age at Death (AD) for the total US population (2017).\
Left panel: Distribution by age. On the x-axis, -100 corresponds to the year 1917, and +100 corresponds to the year 2117. Years lived before 2017 are observed, whereas years lived after 2017 are expected. Right panel: Distribution by AD.](pone.0235955.g001){#pone.0235955.g001}

For individuals who get a disease, D, at a particular age, ([1](#pone.0235955.e008){ref-type="disp-formula"}) becomes $${AD}_{D}\left( {age} \right) = age + {LY}_{\mspace{720mu} D}^{future}\left( {age} \right).$$

${LY}_{\mspace{720mu} D}^{future}$ is calculated similarly to LY^future^. Instead of pop(age), we use I~D~(age) × pop(age) ([Table 1](#pone.0235955.t001){ref-type="table"}), and instead of mortality rates for the general population, we use those of individuals with condition D, q~D~ ([Table 1](#pone.0235955.t001){ref-type="table"}). For diseases with very high mortality, ${LY}_{\mspace{720mu} D}^{future}$ will be small for all ages, and AD~D~ will therefore to a large extent depend on age alone. If the excess mortality is low, the situation resembles that of ([1](#pone.0235955.e008){ref-type="disp-formula"}).

[Fig 2](#pone.0235955.g002){ref-type="fig"} shows the estimated AD distribution among the 10,600 people with incident cases of acute myeloid leukemia (AML) and 1,950 people with incident cases of acute lymphoid leukemia (ALL) in the United States in 2017. We see that average AD was 68.8 for AML and 68.5 for ALL. However, as the figure shows, the mean age of onset was 62.5 for AML and 45.6 for ALL, and mean ${LY}_{\mspace{720mu} AML}^{future}$ was 6.3 years, whereas ${LY}_{\mspace{720mu} ALL}^{future}$ was 22.9 years. Once again, we see that important information about lifetime health is lost when focusing on averages only.

![Estimated Age at Death (AD) for individuals who got leukemia in the US in 2017, sorted according to age at onset.\
Left panel: Distribution for acute myeloid leukemia (AML). Right panel: Distribution for acute lymphoid leukemia (ALL).](pone.0235955.g002){#pone.0235955.g002}

Part II. Adjust for morbidity {#sec010}
-----------------------------

Non-fatal morbidities should also be considered when assessing lifetime health at disease onset, so that one can compare across fatal and non-fatal diseases with different impacts on health loss. This includes estimating health adjusted age (HAA) and future health adjusted life years (HALY^future^). Expanding on ([3](#pone.0235955.e012){ref-type="disp-formula"}), we get $${HAAD}_{D}\left( {age} \right) = HAA^{past}\left( {age} \right) + {HALY}_{D}^{future}\left( {age} \right),$$

In this section we will explain how to estimate HAA^past^ and ${HALY}_{D}^{future}$ using the baseline disability (i.e., the average disability in the population), dw, and the excess disease-specific disability, dw~D~ ([Table 1](#pone.0235955.t001){ref-type="table"}).

[Fig 3](#pone.0235955.g003){ref-type="fig"} outlines the conceptual structure of the HAAD method, where both past and future health is summed for everyone with one of the four diseases AML, ALL, epilepsy and schizophrenia.

![Outline of the conceptual structure of the Health Adjusted Age at Death (HAAD) method, where we calculate the sum of past health and expected future health for five individuals with different diseases (AML, ALL, epilepsy and schizophrenia).\
For a disease D, the dashed black line is baseline mortality (i.e., average mortality in the population), and the blue line is baseline mortality added to the excess risk of death caused by D. The grey area is HAAD~D~. The orange area is baseline health loss due to disability (dw), and the red area is health loss caused by D (dw~D~). These areas slope upwards because disability increases with age. The sum of the grey, orange and red areas constitute age at death (AD). The top solid black line gives a period after the onset of D when the person had a period of increased mortality (PIM). The bottom line gives a similar period of increased disability (PID). Note that PIM and PID may be over before death occurs because the individual has survived the course of the disease, as seen in the top example, or PIM and PID may last beyond the death because the person died during the course of the disease, as seen in the other examples.](pone.0235955.g003){#pone.0235955.g003}

HAA^past^ is calculated as follows, $${HAA}^{past}\left( c \right) = {\sum_{i = 0}^{c - 1}\left( {1 - dw\left( i \right)} \right)},$$ where, *c* is current age and dw(i) is the baseline disability from age "i" to "i+1" ([Table 1](#pone.0235955.t001){ref-type="table"}). We assume that conditions are independent and that past dw are the same regardless of current disease status.

To account for future non-fatal health loss caused by a disease, D, we use disease specific excess disability, dw~D~, and mortality, q~D~, as calculated in [Table 1](#pone.0235955.t001){ref-type="table"}. However, mortality risk is returned from q~D~ to q after a period of increased mortality (PIM), and morbidity returns from dw~D~ to dw after a period of increased disability (PID) ([Table 1](#pone.0235955.t001){ref-type="table"} expands on PIM and PID).

In [Fig 3](#pone.0235955.g003){ref-type="fig"} we see from the AML examples how two different persons may fare under the same PIM and PID. Person 1 survives long enough that both mortality and morbidity return to those of the baseline population, and then dies at age 63 from a different cause, whereas Person 2 dies during the PIM.

Future health adjusted life years, as a function of current age and expected age at death, is $${HALY}_{D}^{future}\left( {c,d} \right) = \left\{ \begin{array}{r}
{0.5 \times \left( {1 - {dw}_{D}^{PID}\left( d \right)} \right),\text{c} = \text{d}\mspace{720mu}} \\
{\left( {c + 0.5} \right) - \left( {0.5 \times {dw}_{D}^{PID}\left( d \right) + {\sum_{i = c}^{d - 1}{{dw}_{D}^{PID}\left( i \right)}}} \right),\text{c} < \text{d}} \\
{- ,\mspace{720mu}\text{c} > \text{d}} \\
\end{array}, \right.$$ where *c* is current age and *d* is expected age at death. Note that it is only necessary to sum over time when *c\<d*. As in ([5](#pone.0235955.e019){ref-type="disp-formula"}), ${dw}_{D}^{PID}\left( i \right)$ is the disability weight from age "i" to "i+1". However, because we estimate future health loss, the disability weight must be adjusted during PID. This means that the disability increased for a period of PID years after onset before returning to that of the general population ([Table 1](#pone.0235955.t001){ref-type="table"}).

We next set out to estimate the HAAD distribution in a population. This is done in several steps. First, we create one matrix for past health, and one for future health. The matrix for past health is $$\mathbb{H}^{past} = \begin{bmatrix}
0 & 0 & \cdots & \cdots & 0 \\
 - & {{HAA}^{past}\left( 1 \right)} & \cdots & \cdots & {{HAA}^{past}\left( 1 \right)} \\
 - & - & {{HAA}^{past}\left( 2 \right)} & \cdots & {{HAA}^{past}\left( 2 \right)} \\
 - & - & - & \ddots & \vdots \\
 - & - & - & - & {{HAA}^{past}\left( Y \right)} \\
\end{bmatrix},$$ where HAA^past^ is from ([5](#pone.0235955.e019){ref-type="disp-formula"}). Because the row number represents current age, we see that the elements are the same within each row. In other words, your past health only depends on your current age, and not your future expected age at death (column number).

In the matrix for future health, we need to account for both current age and expected age at death. Using ${HALY}_{D}^{future}$ from ([6](#pone.0235955.e020){ref-type="disp-formula"}), we get $$\mathbb{H}_{D}^{future} = \begin{bmatrix}
{{HALY}_{D}^{future}\left( 0,0 \right)} & {{HALY}_{D}^{future}\left( 0,1 \right)} & \cdots & {{HALY}_{D}^{future}\left( 0,Y \right)} \\
 - & {{HALY}_{D}^{future}\left( 1,1 \right)} & \cdots & {{HALY}_{D}^{future}\left( 1,Y \right)} \\
 - & - & \ddots & \vdots \\
 - & - & - & {{HALY}_{D}^{future}\left( Y,Y \right)} \\
\end{bmatrix}.$$

Adding past and future health yields $$\mathbb{H}_{D}^{HAAD} = \mathbb{H}^{past} + \mathbb{H}_{D}^{future}.$$

In $\mathbb{H}_{D}^{HAAD}$, row number *c* estimates HAAD for individuals who are *c* years old, whereas column number *d* estimates HAAD for individuals who will die at age *d*. As opposed to the discrete AD, HAAD is continuous. For example, one individual who dies at age 80 may have HAAD = 67.3, whereas another could have achieved 67.4 or 67.5. Because we do not have access to data on individuals, every individual with the same condition and the same age of onset is assumed to have the same HAAD distribution. In ℕ~AD~ from ([2](#pone.0235955.e009){ref-type="disp-formula"}), we obtained these distributions by considering the rows. This information is not available in $\mathbb{H}_{D}^{HAAD}$, but we may create a new matrix, $\mathbb{N}_{AD}^{PIM}$, where the elements correspond to those of $\mathbb{N}_{AD}$, but are calculated using $q_{D}^{PIM}$ instead of q ([Table 1](#pone.0235955.t001){ref-type="table"}).

Pairing all elements in $\mathbb{N}_{AD}^{PIM}$ with the corresponding element in $\mathbb{H}_{D}^{HAAD}$ yields the estimated HAAD distribution for all values of *c* and *d* for the disease D.

In $\mathbb{N}_{AD}^{PIM}$ we use incidence to identify those who get the disease D each year, which is especially useful for life-long conditions. See A1 Fig in ([S1 Appendix](#pone.0235955.s001){ref-type="supplementary-material"}) for details on incidence assumptions that are being used in HAAD calculations for AML and ALL in the US.

[Fig 4](#pone.0235955.g004){ref-type="fig"} shows that even though the estimated aHAAD is similar for AML (59.3) and ALL (58.4), the distribution across individuals is different. For example, in the US we expect 4.6% of individuals with ALL to have HAAD \< 20 (T20), compared with only 2.0% for individuals with AML. Hence, considering risk of attaining little lifetime health, individuals with ALL would be worse off. Still, the 75^th^ percentile (Q3) of HAAD for individuals with ALL (72.2) was higher than in people with AML (68.2), so with respect to chance of attaining much lifetime health individuals with AML would be the worse off. Again, this highlights the need for distributional concerns in policy making.

![Estimated distribution of Health Adjusted Age at Death (HAAD) in the United States in 2017.\
Left: Acute myeloid leukemia (AML). Right: Acute lymphoid leukemia (AML).](pone.0235955.g004){#pone.0235955.g004}

Results {#sec011}
=======

[Table 2](#pone.0235955.t002){ref-type="table"} shows estimated aHAAD, T20, Q1 and Q3 for ALL, AML, schizophrenia and epilepsy in six countries (see A4 Table in [S1 Appendix](#pone.0235955.s001){ref-type="supplementary-material"} for 200 NCDI conditions). Rank orders of the four conditions varied both between countries and according to measure of who is worse off.

10.1371/journal.pone.0235955.t002

###### Average Health Adjusted Age at Death (aHAAD), T20, Q1 and Q3 for four conditions in six countries, results from 200 NCDI conditions can be found in the Appendix Table A4 (the GBD 2017 study \[[@pone.0235955.ref020]\] is source for all calculations).

![](pone.0235955.t002){#pone.0235955.t002g}

                     Acute lymphoid leukemia   Acute myeloid leukemia   Epilepsy   Schizophrenia
  ---------- ------- ------------------------- ------------------------ ---------- ---------------
  Ethiopia   aHAAD   34.8                      32.7                     36.9       41.2
  T20 (%)    44.8    38.7                      14.0                     0.5        
  Q1         8.6     8.7                       26.3                     35.7       
  Q3         62.2    54.4                      46.4                     46.0       
  Haiti      aHAAD   35.1                      35.1                     39.7       40.8
  T20 (%)    41.8    30.1                      8.2                      0.5        
  Q1         9.7     14.9                      30.6                     35.3       
  Q3         60.2    52.8                      48.6                     45.6       
  China      aHAAD   58.3                      48.0                     56.8       45.7
  T20 (%)    5.0     14.3                      1.8                      0.1        
  Q1         48.4    33.2                      50.6                     39.3       
  Q3         72.3    64.3                      65.7                     51.5       
  Mexico     aHAAD   46.0                      41.1                     53.6       44.5
  T20 (%)    22.3    21.5                      2.0                      0.2        
  Q1         21.4    22.6                      46.8                     38.7       
  Q3         68.3    59.1                      61.8                     49.8       
  US         aHAAD   58.4                      59.3                     58.9       43.6
  T20 (%)    4.6     2.0                       0.7                      0.2        
  Q1         50.4    53.4                      53.4                     38.3       
  Q3         72.2    68.2                      66.7                     48.0       
  Japan      aHAAD   66.0                      63.5                     64.4       48.7
  T20 (%)    1.5     1.5                       0.6                      0.0        
  Q1         61.4    58.1                      59.2                     42.3       
  Q3         77.2    72.9                      72.5                     54.5       

T20: Proportion of individuals with disease who attain HAAD \< 20.

Q1: Attained HAAD for the individual at the 25^th^ percentile

Q3: Attained HAAD for the individual at the 75^th^ percentile

The estimated HAAD distribution for schizophrenia was similar across the six settings, although Japan stands out in a positive manner. The difference in Q1 for schizophrenia between the US and Japan was larger than the difference between the US and Ethiopia (Haiti 35.3, Ethiopia 35.7, China 39.3, Mexico 38.7, US 38.3, Japan 42.3). The same applies to aHAAD. T20, the proportion of people with an estimated HAAD \<20, was low across countries for schizophrenia, which is reasonable, as schizophrenia rarely manifests in childhood. Variability in Q1 for epilepsy between countries was high (Ethiopia 26.3, Haiti 30.6, Mexico 46.8, China 50.6, US 53.4, Japan 59.2), and the estimated HAAD distribution for epilepsy was much more unequal within countries with a low Q1 (difference between quartiles (Q3-Q1) was 19.9 in Ethiopia, 18.0 in Haiti, 15.1 in China, 15.0 in Mexico, 13.3 in the US, and 13.3 in Japan). Further, only 0.6% of the Japanese had an estimated HAAD below 20, but the number was 14.0% among Ethiopians and 8.2% among Haitians.

Discussion {#sec012}
==========

According to fairness concerns, limited health care resources should be allocated to interventions that benefit the worse off in society \[[@pone.0235955.ref005]--[@pone.0235955.ref007], [@pone.0235955.ref018]\]. In this paper, we present a quantitative method for identifying the worse off by estimating the distribution of lifetime health across individuals in the same disease category. We show how two conditions, ALL and AML, with similar estimated aHAADs have substantially different HAAD distributions. In addition, we show how HAAD varies across countries, and demonstrate how the HAAD distribution captures different aspects of the fact that diseases are typically more severe in low-income than in high-income countries. Our new framework is important for priority setting because it can be used to assign extra value to health gains from interventions targeting the worse off. The relevance of HAAD is particularly good for preventive interventions for a disease where you are likely to capture benefits across a range of ages (for example treating strep throat in school children to prevent rheumatic heart disease).

Sullivan, in 1971, suggested how morbidity adjustment could be done for LE to get HALE by modifying the standard life table model to estimate the expected duration of a condition by exposing a birth cohort of a disease specific mortality and disability rate over a lifetime \[[@pone.0235955.ref022]\]. Sullivan's method estimates average expected years of healthy life rather than the distribution of HAAD between individuals as done in this paper.

In this article we present HAAD as an achievement measure, but it may be more intuitive to measure shortfall of lifetime health from what someone could potentially achieve. HAAD could be converted to such a gap-measure by using the YLL method applied in GBD. Shortfall in life years could be calculated at disease onset by using the lowest mortality by age in the world as a reference. Shortfall in disabilities could use the lowest YLD rates (i.e., YLD *per capita*) across countries as a reference for disability shortfall. However, disease shortfall measures are beyond the scope of this paper.

PIM and PID, as presented in this paper, have some limitations. They could be different for the same condition across settings, as would be the case for conditions, like HIV, that can be treated or controlled more effectively in some countries than in others. Part of these differences should be captured in the excess mortality differences between countries in our current analysis, but the durations of the periods are also likely to vary. Additionally, PIM and PID do not capture the nature of conditions where mortality and morbidity have complicated temporal patterns. For example, the peak increase in mortality risk for HIV patients is about a decade after onset. At a conceptual level, these obstacles are easy to handle. One simply must estimate PIM and PID for all conditions under consideration in all relevant settings. However, the empirical task of getting precise PIM and PID estimates is not trivial.

Understanding the underlying reasons for differences in HAAD distributions can have policy implications. Observed differences in the distribution between countries can originate from several reasons. It is important to note that as a measure of lifetime health among people with a specific condition, HAAD is influenced by mortality risk and morbidity from other causes, as well as by the age at which the disease occurs. Thus, variation in HAAD could be caused from differences in demography and epidemiology at the country level, or from variations in access to health care that underlie differences in disease-specific morbidity or mortality rates. The relative contribution of each of these differences to the overall difference in HAAD between countries depends on which countries are being compared. How to quantify the role of each factor is discussed further in [S1 Appendix](#pone.0235955.s001){ref-type="supplementary-material"} of (A2 Fig).

To measure the true disease-specific lifetime health distribution, the past health would be calculated using observed past disability for individuals. The estimates available from the GBD Study used as input for our calculations were limited in several ways. Although estimates for 282 causes of death and 354 conditions from the GBD were available by five-year age groups and both sexes for 195 countries, these estimates are based on sparse data in many low- and middle-income countries and rely heavily on modeled relationships with covariates and other data from the same region. There was no individual-level morbidity and mortality information, so we used population averages. This meant that we were unable to account for correlation between illnesses. For example, people who die of a car accident at age 45 may be different on average from those who die of a myocardial infarction at age 45 regarding lifestyle (smoking, exercise, diet) and biology (metabolism, genetics), which could affect the risk of other morbidities. As a result, our estimates of HAAD may be high (overestimate lifetime health) for illnesses that are often experienced with comorbidities because they do not capture the higher burden from the associated illnesses. Conversely, our estimates of HAAD may be low (underestimate lifetime health) for illnesses that have few comorbidities. These limitations are especially evident in mental health conditions. The GBD estimates do not attribute any mortality to mental health disorders; however, we know that patients with mental health disorders have higher mortality risk compared to the general population \[[@pone.0235955.ref029]--[@pone.0235955.ref031]\]. Our schizophrenia HAAD results are additionally limited by distributions of disability weights that do not vary along with treatment availability across countries \[[@pone.0235955.ref032]\]. The limited time series available from the GBD meant that we did not have complete historical average disability rates. For consistency, we used age-specific rates of disability for the calculations of past health; however, health achievement in a real population would use historical disability information if available.

Conclusion {#sec013}
==========

Increasing availability of demographic and epidemiologic data creates opportunities for estimating the lifetime health at disease onset to guide priority setting in health care. Policy makers, supported by the ethical literature, may want to give higher priority to the worse off. However, the impact of such fairness concerns to health policy does not match the impact cost-effectiveness analysis has had on policy the last decades. Data availability and lack of rigorous methods for estimating the lifetime health at time of disease onset are likely contributing factors to the negligence of the worse off in de facto health care priority setting. Here we have presented a method for estimating lifetime health by considering HAAD, illustrated with examples how to estimate the distribution of HAAD across individuals, and shown why considering these distributions is relevant for priority setting in health care and the measurement of population health. We lay the foundations for undertaking detailed calculations of disease-specific HAAD in multiple countries.

Supporting information {#sec014}
======================

###### \[[@pone.0235955.ref020]\], \[[@pone.0235955.ref033]\].

(DOCX)

###### 

Click here for additional data file.

AD

:   age at death

ALL

:   acute lymphoid leukemia

AML

:   acute myeloid leukemia

CEA

:   cost-effectiveness analysis

DALY

:   disability-adjusted life-years

GBD

:   Global Burden of Diseases

HAA

:   health adjusted age

HAAD

:   Health adjusted age at death

HALE

:   healthy life expectancy

HALY

:   healthy life years

PID

:   Period of Increased Disability

PIM

:   Period of Increased Mortality

YLD

:   years lived with disability

YLL

:   years of life lost
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Review Comments to the Author

Reviewer \#1:

Major comments

1\. I am uneasy with the term 'baseline health' used to define both past and expected future health. 'Baseline' makes me think of the health status of an individual/population at a point in time, rather than also being 'conditioned' on future health. Is there another, better term available?

Reply: We agree that this term is confusing, and now use "health status" throughout the paper.

2\. As iHALE is a distributional measure, reporting average iHALE does not seem insightful (except for when pointing out that two conditions can have similar average iHALE but differ when looking at the distribution, as the authors do). It would make sense to background the average measure in the text.

Reply: This is a good point. We have changed the text (Abstract, last sentence of Results) to more frequently use metrics other than the average:

"Many illnesses, such as epilepsy, are associated with a higher health status in high-income settings (Q1 in Japan=59.1) than in low-income settings (Q1 in Ethiopia=26.3)."

Page 15, paragraph 2:

"The difference in Q1 for schizophrenia between the US and Japan was larger than the difference between the US and Ethiopia (Haiti 35.3, Ethiopia 35.6, China 39.3, Mexico 38.7, US 38.2, Japan 42.1). The same applies to the average HEAD."

Also page 15, paragraph 2:

"Variability in Q1 for epilepsy between countries was high (Ethiopia 26.3, Haiti 30.5, Mexico 46.8, China 50.4, US 53.3, Japan 59.1). In addition, there is a much more unequal HEAD distribution for epilepsy in countries with a low Q1 (difference between quartiles (Q3-Q1) was 19.9 in Ethiopia, 17.9 in Haiti, 15.2 in China, 14.9 in Mexico, 13.3 in Japan, and 13.2 in the US)."

3\. More information on GBD sources are required, as characteristics - particularly the reliability of age-specific prevalence -- would appear vital to the computations of iHALE. Are the illness data adjusted or modelled in any way, or are they taken directly from surveillance systems or routine recording? For some of the countries I am sceptical that data by 5-year age-group would have been available. Please consider the limitations of the GBD source.

Reply: We agree that more information could be added to the paper. We now write (page 8, paragraph 1):

"Estimates for all countries and for all diseases in 2017 are obtained from the freely available GBD results tool \[23\]. The GBD Study produces cause-specific estimates of deaths, incidence, and prevalence by country, year, age, and sex, utilizing demographic methods \[24, 25\], ensemble models \[26\] using vital registration and verbal autopsy data about causes of death, and Bayesian meta-regression \[27\] using data from reviews of literature, registries, and hospitals."

and we discuss several limitations of the input data on page 18, paragraph 1. We have added to that paragraph.

"Although estimates for 282 causes of death and 354 conditions from the GBD were available by five-year age groups and both sexes for 195 countries, these are based on sparse data in many low- and middle-income countries and rely heavily on modeled relationships with covariates and other data from the same region."

Other comments

1\. Intro lines 19-20: the focus is described as how a particular illness affects total lifetime health. It is only future health that can be affected; please edit.

Reply: We agree that the illness itself only affects future expected health. Differences in the distribution of age of onset of diseases also mean that past health differs across diseases. We have more explicitly described these two components of lifetime health in this section. The text now reads (second paragraph of Introduction, final sentence):

"Technically, only the future health (after disease onset) is affected directly by the disease, but lifetime health is the sum of past (before disease onset) and future health expectancies. These differences in years of healthy life lived before disease onset among people with different diseases also inform the potential lifetime health that can be attained and are part of measuring health status by the view we use."

2\. I wonder about the assertion that iHALE 'measures ... health at an individual level' (Abstract and elsewhere); in theory perhaps, but in practice (as demonstrated in the current paper), it is computed for strata of all individuals with a certain condition at a certain age. The authors may wish to re-think the use of 'individual ' and edit appropriately.

Reply: We agree, and now use health expected age at death (HEAD) instead of iHALE. Further, the text has been changed as follows (Abstract, Methods, first sentence):

"HEAD measures health status for individuals with specific conditions, \..."

and (Methods, first sentence)

"HEAD measures lifetime health for individuals with specific conditions, ..."

and (Discussion, third paragraph, 2nd and 3rd sentences)

"HEAD could be converted to a gap-measure by using the YLL method applied in GBD. Shortfall in life years could be calculated at disease onset by using the lowest mortality by age in the world as a reference."

3\. The description of YLD as 'in one particular year' and 'during the year' is only relevant for the prevalence-based approach to computing YLD and DALY, such as used by the GBD project; please clarify.

Reply: We have specified this in the text. (Introduction, 4th paragraph, 3rd sentence:

"GBD uses a prevalence-based approach, where DALYs are calculated for a set of diseases by summing the years of life lost (YLL) compared to a reference life expectancy and years lived with disability (YLD) in one particular year due to each disease"

4\. HALE needs to be defined at first mention.

Reply: The HALE abbreviation is defined in the fourth paragraph in the Introduction. We have added another sentence to this paragraph that describes HALE:

"HALE measures the life expectancy in a population, adjusting for the disability experienced in the population, using age-specific mortality rates and YLDs per capita \[22\]."

5\. Methods line 8. If Ann can die in her 51st year, then it seems that she 'will most certainly die within 21 years' (not 20).

Reply: We agree, and this has been corrected accordingly

6\. Methods/Data lines 9-10. Edit needed - for disease prevalence, the source must not only be the GBD 'cause of death' database.

Reply: We have corrected this mistake, and now refer to "GBD results tool" (second to last sentence, first paragraph in Data). We also changed the reference to the GBD results tool website.

7\. Concl line 4: 'concerned about giving higher priority' is unfortunately ambiguous (ie. want to.. or want to avoid..)

Reply: We agree, and have rephrased (first paragraph in Conclusion, second sentence): "Policy makers, supported by the ethical literature, may want to give higher priority to the worse off."

8\. Concl line 10. 'measure that is sensitive to distribution'. This is a bit awkward.. 'distribution of what'? Please reword, given that iHALE is a distribution, and summary statistics (T20, quartiles etc) can be produced from it.

Reply: We agree that this was vague, and the text now says (second to last sentence in Conclusions):

"Here we have presented a method for calculating HEAD, illustrated with examples how to estimate the distribution of health across individuals, and shown why considering these distributions is relevant for priority setting in health care and the measurement of population health."

9\. Fig 2 : the word 'age' in the plot area is distracting and not described. Also suggest to change 'Mean age' to 'Mean age of onset'

Reply: We have removed "age" from the figure, and corrected "Mean age" as the reviewer suggested.

10\. Fig 3 is very hard to interpret. In the top panel, does 'Death' refer to the red area or to a point in time (on x-axis)? Should the rightmost endcap on PID length not be flush with the right border of the orange area? The text in the red area is illegible. Why do coloured areas slope upwards? Please improve and edit accompanying description.

Reply: The figure text now reads (changes highlighted in \*\...\*):

"Outline of the conceptual structure of the \*Health Expected Age at Death (HEAD)\* method, where we calculate the sum of past health and expected future health for five individuals with different diseases (AML, ALL, epilepsy and schizophrenia). For a disease D, the dashed black line is background mortality, and the blue line is background mortality added to the excess risk of death caused by D. \*The grey area is HEADD\*. The orange area is background health loss due to disability (dw), and the red area is health loss caused by D (dwD). \*These areas slope upwards because disability increases with age.\* The sum of the grey, orange and red areas constitute \*expected age at death (EAD)\*. The top solid black line gives a period after the onset of D when the person had a period of increased mortality (PIM). The bottom line gives a similar period of increased disability (PID). \*Note that PIM and PID may be over before death occurs because the individual has survived the course of the disease, as seen in the top example, or PIM and PID may last beyond the death because the person died during the course of the disease, as seen in the other examples.\*"

Reviewer \#2:

I do not agree that these are outcomes on the level of the individual, as these are measures for groups: groups with the same age and disease. So the i in iHALE to me is not justified.

Reply: We agree, and now use HEAD instead of iHALE (see reply to Reviewer 1).

Page 13 is confusing, as it is unclear what are the data that are used here. Only half way down the page I understood that this are data constructed from life table data, and this part is explaining the conceptual calculations behind the measure. An example of something that put me on the wrong foot was: "First, we define Y, the maximum age in our lifetable, by setting the chance of surviving from age Y to Y+1 to zero." This is not a definition of Y, but a statement that one arbitrarily is assuming a particular Y. Reading this I also want to understand what value Y is used, which is only mentioned much later.

Reply: We have edited the text as follows (Part I: Estimating disease-specific expected age at death, changes in \*\...\*):

"\*To estimate expected age at death (EAD) from the GBD data described in previous sections, we use standard lifetable methodology, so that EAD\* of an individual is simply

EAD(age)=age+LY\^future (age) , (1)

where "age" is the age of the individual and LYfuture is the number of life years they have left to live at their respective age. LYfuture is not known until the individual dies, but its distribution can be estimated as follows. First, we choose Y, the maximum age in our lifetable, by setting the chance of surviving from age Y to Y+1 to zero. \*In principle, Y can be any age, but we have used Y=99 throughout this paper.\*"

Equation (7) needs more explanation, as I can not grasp what is happening here; I seem to me that there is some summation over time missing.

Reply: We have added the following text to clarify:

"...where c is current age and d is age at death. Note that it is only necessary to sum over time when c\<d."

In table 1 it is not clear whether the event rates are rates or one-year probabilities.

Reply: From GBD, prevalence, incidence, and YLDs are rates, not probabilities (the denominator is mid-year population estimates from GBD, which is used as the denominator for rates in GBD). Deaths from GBD were downloaded as rates for 5-year age groups for a single year. To do calculations for specific ages, we assumed the same rate for each single age in the age group. We treated these 1-year rates as probabilities since we're adding rates to rates. Since we used rates (mx) and treated it as probabilities (qx), there could be small differences in results if anyone tries to replicate using qx from GBD.

Also in table 1 it is unclear to me why dw is divided by 100000. YLD is normally given for a population. Is YLD in the formula the YLD for a population of 100000? Is this age dependent?

Reply: The initial downloaded value is the rate of YLDs per 100,000. This is also true for prevalence and incidence, though we specified in the Table that those metrics are given per population. We have changed the description to reflect that YLDs are also given per population and changed the equations for dw and dwD accordingly. These rates are age-specific, which we have added to the formula. These are the new formulas:

dw(age)=YLD\_(All causes) (age)

dw_D (age)=(YLD_D (age))/(P_D (age))

More explanation is needed, also for the formula used in the last row of the table.

Reply: We have added detail on the last row of the table for the disability weight during the period of increased disability. The description now reads as follows:

"In the GBD study, disability weights are aggregated by subtracting from 1 the product of 1 minus the two disability weights. To calculate the disability weight during the period of increased disability during illness, we can combine the "background" disability from other causes on average and the disability specifically from the disease on average.

dw_D\^PID (age)=1-(1-dw_Background (age))(1-dw_D (age)) .

To calculate the background disability, we treat YLD rates in the population as average disability weights for a given person and solve for the background disability by breaking down the all-cause disability weight into disability from the specific cause and from other causes.

YLD\_(All Causes) (age)=1-(1-dw_Background (age))(1-YLD_D (age))

Solving for the background disability and inserting into the first equation, the disability weight during the period of increased disability is

dw_D\^PID (age)=1-(1-(〖YLD 〗\_(All causes) (age)-YLD_D (age) )/(1-YLD_D ))(1-dw_D ) .

After the period, dw returns to that of the background population (dw)."
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Dear Mr. Haaland,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Apr 16 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A [**rebuttal letter**]{.ul} that responds to [**EACH**]{.ul} point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A [**marked-up copy**]{.ul} of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An [**unmarked version**]{.ul} of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Brecht Devleesschauwer

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Both reviewers appreciated the revisions made by the authors, but made some further suggestions for improvement. In your revision note, please include EACH comment of the reviewers, provide your reply, and when relevant, include the modified/new text (or motivate why you decided not to modify the text).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this revised version and response letter I believe the authors have adequately addressed all comments and concerns raised on the originally submitted manuscript. However, there is now a overlap of terminology, especially caused by the change of name of the new distributional measure they are proposing - HEAD - and the reader will be as confused as the reviewer.

First, why (besides forming a convenient English-acronym) was the change to HEAD made? \'Health expected age at death\' does not make sense to me. \'Expected age at death\' does, including the provision (Eq 4) that the expected life years remaining is dependent on the disease that an individual has at age \'age\'. The vital difference between EAD and the HEAD measure (if I understand correctly) is that in the latter life-years are adjusted for experienced disability/non perfect health; this is the main reason why \'age at death\' is not an accurate descriptor. Please improve the name. Related to this comment, T2 and other reported distribution-summaries refer to \'healthy life years\' in the text when I guess they should have referred to \'HEAD; this is confusing.

Second, what is the difference between \'health status\' and \'lifetime health\'? They seem to be used interchangeably throughout the paper. \'Health status at disease onset\' should not include the \'future health\' component (but is used - I think - when discussing HEAD, for instance 1st sentence of Conclusion, and in 3rd para of Introduction (it is not intuitive to me that young MS patients have a \'low health status\').

Third, what do \'background mortality\' and \'background disability\' mean? Please explicitly define.

Reviewer \#2: The new version is somewhat improved, but important points have not yet been resolved, especially with regards to the formula in table 1. Below my specific comments.

1\. The proposed metric now has a new name. Although this omits \"individual\", it still does not cover the content of the new concept, as the concept seems to be "expected healthy years lived until death"

In this sense I would considered this to be simple a HALE, but calculated for a subgroup of the population (the group that is diagnosed with a particular disease at a certain age). Therefore I wonder if a new term is needed at all. I would suggest a name that reflects this is a type of HALE (e.g. HALE-AD ) (HALE by age of disease incidence).

2\. One big problem with this paper is that it seems to use the terms YLD and dw at some places as a kind of synonyms, while these are quit different concepts.The authors should fix this problem with the paper, as this prevents me from fully understanding their calculations.

Some examples of this:

Table 1:

dw(age) = YLDAll causes(age)

How can this be? YLD is a number for the population, which will be much larger then 1, while dw is between 0 and 1.

Because of this I can also no follow the next part in the last row of the table:

YLD.All Causes(age) = 1 − (1 − dwBackground(age))(1 − YLDD(age))

Again, 1 - YLD does not make sense to me, as YLD usually is much larger than 1.

Similarly, in the text of the introduction: "HALE measures the life expectancy in a population, adjusting for the disability experienced in the population, using age-specific mortality rates and YLDs per capit". HALE does not use YLDs but dw's.

3\. The calculations treat rates as probabilities. This will work reasonably as long as rates are low. However, they will no longer be so at high ages. Why do you not simple use prob =1- exp(-rate\*interval length) (assuming a constant rate in the interval) to calculate the probability?

4\. Methods, line 13: The use of "health status" here is confusing, as the example only refers to being alive.

5\. Methods, line 21: Here it is claimed that HEAD also looks at distributions, while in the example only the average (=expectancy) is used. I therefore could not follow the reasoning in this part.

6\. At parts the text still pertains that the metric is for individuals (while the metric is for groups of individuals). For instance in the conclusion:

"Here we have presented a method for calculating HEAD, illustrated with examples how to estimate the distribution of health across individuals"

7\. In the legend of figure 3 it is strange that PID is shorter than PIM. Although this is just a legend, it confuses.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

11 May 2020

Response to reviewers, part II

Dear editor

Please find our replies to the reviewers below.

Reviewer \#1:

First, why (besides forming a convenient English-acronym) was the change to HEAD made? \'Health expected age at death\' does not make sense to me. \'Expected age at death\' does, including the provision (Eq 4) that the expected life years remaining is dependent on the disease that an individual has at age \'age\'. The vital difference between EAD and the HEAD measure (if I understand correctly) is that in the latter life-years are adjusted for experienced disability/non perfect health; this is the main reason why \'age at death\' is not an accurate descriptor. Please improve the name.

We have now changed the name to Health Adjusted Age at Death (HAAD), and hope that this addresses the concern of the reviewer. Both "Life Expectancy" and "Age at Death" are measured in years, and these years can be health adjusted. In principle, HALE at birth is the same as expected HAAD at birth.

We will also get back to the name of the metric in our reply to R2.

Related to this comment, T2 and other reported distribution-summaries refer to \'healthy life years\' in the text when I guess they should have referred to \'HEAD; this is confusing.

We agree, and now use HAAD where appropriate (twice in the final sentence in Methods section in the Abstract).

Second, what is the difference between \'health status\' and \'lifetime health\'? They seem to be used interchangeably throughout the paper. \'Health status at disease onset\' should not include the \'future health\' component (but is used - I think - when discussing HEAD, for instance 1st sentence of Conclusion, and in 3rd para of Introduction (it is not intuitive to me that young MS patients have a \'low health status\').

We think it is appropriate to use "health status" early in the Introduction, when we discuss the three perspectives current health, future health, and lifetime health. However, starting from the fourth paragraph of the Introduction, we now use "lifetime health" instead of "health status".

We have changed the last sentence in the third paragraph of the Introduction: "Conditions that are severe from a lifetime health perspective, like multiple sclerosis in young patients, do not necessarily require urgent interventions. To underscore that we use a lifetime health perspective when measuring health status, we will from now on use the term "lifetime health" instead of "health status"."

Third, what do \'background mortality\' and \'background disability\' mean? Please explicitly define.

We agree that this was confusing, and have made the following changes in the manuscript:

We have introduced "baseline mortality" and "baseline disability" to separate between the mortality and disability among all people in the population (baseline) and mortality and disability among all people in the population without condition D (background).

The first sentence below Eq. (5) now reads "In this section we will explain how to estimate HAApast and HALY_D\^future using the baseline disability (i.e., the average disability in the population), dw, and the excess disease-specific disability, dwD (Table 1)."

The row explaining q in Table 1 now reads: "All cause probability of death in single-year intervals, for a total population (i.e., baseline mortality)."

The legend and figure text of Figure 3 now use "baseline" instead of "background", and the text includes the sentences:

"For a disease D, the dashed black line is baseline mortality (i.e., average mortality in the population), ..."

We use "background disability" and "background mortality" to describe the disability and mortality of those individuals in the population who do not have condition D.

The row explaining dw_D\^PID now includes the sentence "To calculate the disability weight during the period of increased disability during illness, we can combine the "background" disability (i.e., disability from other causes than D) on average and the disability specifically from the disease on average."

Reviewer \#2:

The proposed metric now has a new name. Although this omits \"individual\", it still does not cover the content of the new concept, as the concept seems to be "expected healthy years lived until death"

In this sense I would considered this to be simple a HALE, but calculated for a subgroup of the population (the group that is diagnosed with a particular disease at a certain age). Therefore I wonder if a new term is needed at all. I would suggest a name that reflects this is a type of HALE (e.g. HALE-AD ) (HALE by age of disease incidence).

We have now changed the name to Health Adjusted Age at Death (HAAD). We do not agree that this is HALE for a subgroup of the population, because HALE considers future healthy life expectancy only. This also applies to LE (e.g., LE for a 99-year-old is about 1).

Further, we do not agree that we should include "age of disease" or a similar phrase in the name, because one could calculate HAAD for individuals who are not affected by a condition (similar to what we did in Figure 1).

Next, we have removed the word "expected/expectancy" from the name, because this obscures the concept of HAAD. For example, one could discuss the HAAD of disease D without knowing the expected HAAD of an individual or a group of individuals. Instead we use other words to describe the context in which HAAD is used, and introduce "aHAAD" as "average lifetime health/average HAAD". See for example

Title:

"Estimating Health Adjusted Age at Death" instead of "Measuring Health Adjusted Age at Death"

Introduction:

"In this paper, we present a method for estimating HAAD, and show how to use the estimated HAAD to rank conditions at disease onset"

Methods:

"The diseases have distinct properties that highlight certain characteristics of HAAD."

"We next set out to estimate the HAAD distribution in a population"

"In H_D\^HAAD, row number c estimates HAAD for individuals who are c years old, whereas column number d estimates HAAD for individuals who will die at age d."

"As opposed to the discrete AD, HAAD is continuous. For example, one individual who dies at age 80 may have HAAD=67.3, whereas another could have achieved 67.4 or 67.5."

"Because we do not have access to data on individuals, every individual with the same condition and the same age of onset is assumed to have the same HAAD distribution."

"See Figure A1 (Appendix) for details on incidence assumptions that are being used in HAAD calculations for AML and ALL in the US."

Results:

"Table 2 shows estimated aHAAD, T20, Q1 and Q3 for ALL, AML, schizophrenia and epilepsy in six countries"

Discussion:

"We show how two conditions, ALL and AML, with similar estimated aHAADs have substantially different HAAD distributions."

"The relevance of HAAD is particularly good for preventive interventions for a disease where you are likely to capture benefits across a range of ages"

"In this article we present HAAD as an achievement measure"

"Understanding the underlying reasons for differences in HAAD distributions can have policy implications."

"It is important to note that as a measure of lifetime health among people with a specific condition, HAAD is influenced by mortality risk and morbidity from other causes, as well as by the age at which the disease occurs"

One big problem with this paper is that it seems to use the terms YLD and dw at some places as a kind of synonyms, while these are quit different concepts.The authors should fix this problem with the paper, as this prevents me from fully understanding their calculations.

Some examples of this:

Table 1:

dw(age) = YLDAll causes(age)

How can this be? YLD is a number for the population, which will be much larger then 1, while dw is between 0 and 1.

Because of this I can also no follow the next part in the last row of the table:

YLD.All Causes(age) = 1 − (1 − dwBackground(age))(1 − YLDD(age))

Again, 1 - YLD does not make sense to me, as YLD usually is much larger than 1.

Similarly, in the text of the introduction: "HALE measures the life expectancy in a population, adjusting for the disability experienced in the population, using age-specific mortality rates and YLDs per capit". HALE does not use YLDs but dw's.

Reply: We understand that this was confusing. GBD calculates YLDs by summing dw's over all individuals in the population. Hence,

average dw = YLD/(population size) .

In other words, dw is per capita YLD, and

and

average dw for disease D = (YLD caused by disease D)/(population with disease D) .

Changes: We have changed the text in Table 1 and emphasized on several occasions that YLD is per capita.

Discussion:

"Shortfall in disabilities could use the lowest YLD rates (i.e., YLD per capita) across countries as a reference for disability shortfall."

Table 1

"Note that YLD\_(All causes) (age) is per capita."

"Note that YLD_D (age) is per capita."

"To calculate the background disability, we treat YLD rates (i.e., YLD per capita) in the population as average disability weights for a given person and solve for the background disability by breaking down the all-cause disability weight into disability from the specific cause and from other causes."

"Note that YLD\_(All causes) (age) and YLD_D (age) are per capita."

The calculations treat rates as probabilities. This will work reasonably as long as rates are low. However, they will no longer be so at high ages. Why do you not simple use prob =1- exp(-rate\*interval length) (assuming a constant rate in the interval) to calculate the probability?

As suggested, we have changed all of our calculations using q = 1-exp(-M), where M is the mortality rate and q is the probability of dying during a year. The interval length is 1 in all our calculations.

We have also clarified the difference between mx and qx in Table 1:

"All cause probability of death in single-year intervals, for a total population (i.e., baseline mortality).

From GBD 2017.

q=1-exp⁡(-M\_(All causes) )

Converted from single-year MD using common demographic approximation \[32\]."

and

"Probability of death due to disease and baseline mortality. These are not given directly in GBD, but can be calculated using

q_D (age)=1-exp⁡(-(M\_(All causes) (age)-M_D (age)+em_D (age))) .

Substituting emD into qD yields

q_D (age)=1-exp⁡(-(M\_(All causes) (age)+M_D (age)(1/(P_D (age) )-1))) .

We can see that if PD=1, meaning that all individuals in the population have a disease, qD simply becomes q. This is also the case if there is no mortality from disease, so that MD=0."

Methods, line 13: The use of "health status" here is confusing, as the example only refers to being alive.

We have changed the relevant text to:

"For simplicity in this example, although we will use the term "lifetime health", we disregard health/disability adjustment for time with illness and focus only on their age at death. Because there is a 99% probability that Ann will die at a younger age than Bob will, Ann's lifetime health is lower than Bob's in terms of total length of life (past life plus expected future life), even though Bob's expected future life is shorter."

Methods, line 21: Here it is claimed that HEAD also looks at distributions, while in the example only the average (=expectancy) is used. I therefore could not follow the reasoning in this part.

We have changed the text to:

"HAAD enables comparison of both average lifetime health (aHAAD) and distribution of lifetime health between individuals with different diseases (e.g., at disease onset, Ann's disease will have a very different HAAD distribution than Bob's disease)."

At parts the text still pertains that the metric is for individuals (while the metric is for groups of individuals). For instance in the conclusion:

"Here we have presented a method for calculating HEAD, illustrated with examples how to estimate the distribution of health across individuals"

In principle, HAAD could be used at an individual level, but that would require information about disease history and age at death. However, as the reviewer correctly points out, the aim of this paper is to estimate HAAD for groups of individuals. Still, we focus on the estimated HAAD distribution across those individuals.

We have changed the relevant text:

"Here we have presented a method for estimating lifetime health by considering HAAD, illustrated with examples how to estimate the distribution of HAAD across individuals, and shown why considering these distributions is relevant for priority setting in health care and the measurement of population health."

In the legend of figure 3 it is strange that PID is shorter than PIM. Although this is just a legend, it confuses.

We have changed Fig 3 so that PID is now longer than PIM.

Because we changed the calculations (as suggested) by using q = 1-exp(-M), the figures and tables changed. We have also edited the manuscript for clarity.

Best wishes,

On behalf of the authors,

Øystein A. Haaland
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Click here for additional data file.
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10 Jun 2020

PONE-D-19-18816R2

Estimating Health Adjusted Age at Death (HAAD)

PLOS ONE

Dear Dr. Haaland,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 25 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A [**rebuttal letter**]{.ul} that responds to [**EACH**]{.ul} point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A [**marked-up copy**]{.ul} of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An [**unmarked version**]{.ul} of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Brecht Devleesschauwer

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The reviewer raised some final points, in particular related to the terminology used, which can be addressed in a final, minor revision round.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have achieved a lot with respect to clarification and use of terminology since the previous revision.

Main remaining point to be addressed:

The use of disability weight (dw) to stand for disability as a quantity with a time dimension will be very confusing to the reader familiar with \'dw\' as an elicited weight (not something that can be seen as a population average, or that necessarily can be decomposed).

In Table 1, the authors describe the calculation of \"\... the background disability, we treat YLD rates (i.e., YLD per capita) in the population as average disability weights for a given person and solve for the background disability by breaking down the all-cause disability weight into disability

from the specific cause and from other causes.

I would ask the authors to not conflate disability weight and YLD rate, and so choose terms that do not overlap with \'standard\' burden of disease terminology.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 2

13 Jun 2020

Dear editor

Please find our replies to the reviewers below.

Reviewer \#1:

Comment:

"The authors have achieved a lot with respect to clarification and use of terminology since the previous revision.

Main remaining point to be addressed:

The use of disability weight (dw) to stand for disability as a quantity with a time dimension will be very confusing to the reader familiar with \'dw\' as an elicited weight (not something that can be seen as a population average, or that necessarily can be decomposed).

In Table 1, the authors describe the calculation of \"\... the background disability, we treat YLD rates (i.e., YLD per capita) in the population as average disability weights for a given person and solve for the background disability by breaking down the all-cause disability weight into disability from the specific cause and from other causes.

I would ask the authors to not conflate disability weight and YLD rate, and so choose terms that do not overlap with \'standard\' burden of disease terminology."

Reply:

Although we understand the concern of the reviewer, according to the GBD, "YLDs were estimated as the product of prevalence estimate and a disability weight for health states \[...\]" (Lancet 2018; 392: 1789--858). In Table 1 this corresponds to:

dw_D (age)=(YLD_D (age))/(P_D (age)) ,

and the rest of the derivations follow from this. This terminology may be confusing, but we worry that it will be even more confusing if we introduce new terminology do describe the relationship between YLDs and disability weights. Therefore, we prefer to keep the terms YLD and "disability weight" as they are.

To explain the GBD approach, the Introduction says:

"GBD uses a prevalence-based approach, where DALYs are calculated for a set of diseases by summing the years of life lost (YLL) compared to a reference life expectancy and years lived with disability (YLD) in one particular year due to each disease \[19\]. For a particular condition and a particular year, YLL is the sum of all the years lost for the individuals who died from the condition during that year. The reference is the age-adjusted life expectancy (LE) from a life table derived from the mortality rates in the locations with the lowest age-specific mortality in the GBD study \[20\]. YLD, on the other hand, is the sum of the health loss due to the condition during the year across people living with the condition \[21\]. DALYs aggregated from YLLs and YLDs are a measure of overall population burden. HALE measures the life expectancy in a population, adjusting for the disability experienced in the population, using age-specific mortality rates and YLDs per capita \[22\]."

In Table 1 the definition of YLD_D now reads:

"Years Lived with Disability (per capita in one year) of disease in 5-year age intervals.

From GBD 2017.

Assumed to be the same in all 1-year intervals."

We hope that you find this line of reasoning convincing.

Best wishes,

On behalf of the authors,

Øystein A. Haaland
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Dear Dr. Haaland,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Brecht Devleesschauwer

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0235955.r008
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Estimating Health Adjusted Age at Death (HAAD)

Dear Dr. Haaland:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dr. Brecht Devleesschauwer

Academic Editor

PLOS ONE
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